Related Experiment Videos
Workshop: options for therapy in ovarian cancer
Thomas J Herzog1, Robert W Holloway, Gavin C E Stuart
1Division of Gynecologic Oncology, Washington University Medical Center, St. Louis, MO 63110, USA. herzogt@msnotes.wustl.edu
Gynecologic Oncology
|September 18, 2003
Summary
For ovarian cancer relapses, topotecan or pegylated liposomal doxorubicin are options for platinum-resistant disease. Retreatment with platinum-based chemotherapy is preferred for platinum-sensitive relapses, with other agents for palliation.
Area of Science:
- Oncology
- Gynecologic Oncology
- Cancer Therapeutics
Background:
- Ovarian cancer frequently relapses, necessitating effective sequential therapeutic strategies.
- Managing recurrent ovarian cancer requires careful consideration of prior treatments and platinum sensitivity.
Observation:
- For platinum-resistant first relapse, topotecan or pegylated liposomal doxorubicin are favored, with topotecan potentially better earlier.
- For platinum-sensitive late relapse, retreatment with carboplatin/paclitaxel is often preferred, especially after optimal debulking.
- Subsequent relapses may be managed with alternative agents like liposomal-encapsulated doxorubicin, oral etoposide, gemcitabine, or docetaxel.
Findings:
- Sequential therapy choices depend on platinum sensitivity, timing of relapse, and prior treatment history.
- Topotecan tolerability can be improved with dose/schedule adjustments for relapsed/refractory disease.
- Continuing topotecan or using consolidation therapy may extend progression-free intervals.
Implications:
- Optimized sequential treatment regimens can improve outcomes in recurrent ovarian cancer.
- Personalized therapeutic approaches are crucial for managing platinum-resistant and platinum-sensitive relapses.
- Further research into novel agents and treatment schedules may enhance long-term disease control.